120 related articles for article (PubMed ID: 34625284)
1. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R
Gynecol Oncol; 2021 Apr; 161(1):160-165. PubMed ID: 33608144
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
4. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
5. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Kok PS; Beale P; O'Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; DeFazio A; Mapagu C; Amant F; Friedlander M;
J Gynecol Oncol; 2019 Sep; 30(5):e86. PubMed ID: 31328463
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M;
Gynecol Oncol; 2021 Oct; 163(1):72-78. PubMed ID: 34412908
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M;
Gynecol Oncol; 2019 Jul; 154(1):29-37. PubMed ID: 31130288
[TBL] [Abstract][Full Text] [Related]
8. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
del Carmen MG; Fuller AF; Matulonis U; Horick NK; Goodman A; Duska LR; Penson R; Campos S; Roche M; Seiden MV
Gynecol Oncol; 2003 Dec; 91(3):596-602. PubMed ID: 14675683
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
Kelley TW; Borden EC; Goldblum JR
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):338-41. PubMed ID: 15536333
[TBL] [Abstract][Full Text] [Related]
17. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
Mackay HJ; Buckanovich RJ; Hirte H; Correa R; Hoskins P; Biagi J; Martin LP; Fleming GF; Morgan R; Wang L; Polintan R; Oza AM
Gynecol Oncol; 2012 Apr; 125(1):136-40. PubMed ID: 22138373
[TBL] [Abstract][Full Text] [Related]
18. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]